Enteric Disease Testing Market Analysis

Enteric Disease Testing Market Analysis

To get key market trends

  Download Free Sample

The market by disease is categorized into bacterial enteric disease, viral enteric disease, and parasitic enteric diseases. The bacterial enteric disease segment is further divided into C. difficile, E. coli, salmonella, campylobacter, listeria, and shigellosis. The viral enteric disease segment is further bifurcated into rotavirus infection, and norovirus infection. The parasitic enteric disease segment is further divided into giardiasis, amebiasis, and cryptosporidiosis. The bacterial enteric disease segment accounted for majority share and was valued at over USD 2.1 billion revenue in 2023.
 

• Bacterial enteric diseases, such as salmonellosis, shigellosis, campylobacteriosis, and Escherichia coli (E. coli) infections, are prevalent worldwide. The high incidence of bacterial enteric infections, especially in developing countries with poor sanitation and hygiene standards, underscores the need for effective diagnostic testing to identify the causative agents and implement appropriate treatment and control measures.
   
• Further, ongoing advancements in diagnostic technologies, such as polymerase chain reaction (PCR) assays, multiplex panels, and next-generation sequencing (NGS) platforms, enhance the sensitivity, specificity, and speed of bacterial enteric disease testing. Molecular methods enable the simultaneous detection of multiple bacterial pathogens from clinical specimens, improving diagnostic accuracy and efficiency in clinical microbiology laboratories and public health laboratories.
   

Based on test type, the enteric disease testing market is segmented into immunoassay, molecular, conventional, chromatography & spectrometry, and other test types. The immunoassay segment held leading revenue share in 2023 and is anticipated to reach USD 1.9 billion by 2032.
 

• Immunoassays offer high sensitivity and specificity in detecting specific antigens or antibodies associated with enteric pathogens. These assays can accurately identify target molecules, such as bacterial toxins, viral antigens, or parasitic antigens, present in patient samples, facilitating rapid and reliable diagnosis of enteric diseases.
   
• Moreover, immunoassays often provide rapid results compared to traditional culture-based methods or molecular diagnostics. Rapid diagnostics tests (RDTs) based on immunoassay principles allow for on-site testing and immediate detection of enteric pathogens, enabling timely diagnosis and treatment initiation in clinical settings, emergency departments, and point-of-care environments, thereby leading to the segmental growth.
   

The enteric disease testing market by end-use is categorized into hospitals, diagnostic laboratories, research & academic institutes, and other end-users. The hospitals segment accounted for majority revenue share and was valued at around USD 1.4 billion revenue size in 2023.
 

• Hospitals are the first place of contact for patients seeking medical attention for gastrointestinal symptoms such as diarrhea, vomiting, abdominal discomfort, and fever, that can suggest enteric infections. Prompt and accurate diagnosis of enteric disorders is critical for identifying the underlying microorganisms, evaluating disease severity, and guiding suitable treatment methods in hospitalized patients.
   
• Moreover, hospitals provide a wide range of inpatient and outpatient services, including emergency departments, urgent care centers, specialty clinics, and outpatient laboratories, where enteric disease testing can be performed. Inpatients admitted with suspected enteric infections, as well as ambulatory patients presenting with gastrointestinal symptoms, may require diagnostic evaluation and testing for enteric pathogens during their hospital stay or outpatient visits.
   

North America enteric disease testing market accounted for USD 1.4 billion revenue in 2023 and is predicted to witness substantial market growth.

• North America endures an immense burden of enteric diseases, which include foodborne illnesses, waterborne infections, and outbreaks of gastrointestinal infections caused by bacteria, viruses, and parasites. To combat the effect of these conditions on public health, public health authorities and healthcare institutions focus on enteric disease monitoring, prevention, and control initiatives, leading to increased demand for enteric disease testing services.
   
• Furthermore, the region offers sophisticated healthcare infrastructure, cutting-edge laboratory facilities, and well-equipped clinical microbiology laboratories that can perform a wide range of enteric disease tests, such as microbiological culture, molecular diagnostics, immunoassays, and rapid diagnostic tests (RDTs). Availability to modern diagnostic technology, automated platforms, and qualified laboratory workers allows for efficient and accurate enteric pathogen testing in clinical and public health settings, thus leading to the region growth.